Search
Displaying 221–230 of 664 for “retinitis clinical trial”
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Research NewsThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
ARVO 2015 Highlight: New Research Boosts Prospects for Saving Vision with RdCVF
Research NewsAfter years of refinement and testing in animal models, the emerging therapy is about a year and a half from moving into a clinical trial.
-
A Stem-Cells Video for Kids (and Newbies of All Ages)
Research NewsBiology and genetics can be difficult to understand for even an educated adult, so when something kid-friendly is produced, especially a video, we are eager to share it.
-
Gene Therapy Revives Cones Long After They Stop Working
Research NewsA Foundation-funded research group is developing a gene therapy that revives degenerating cones, enabling them to regain their ability to respond to light and provide vision.
-
Genetic Testing for Inherited Retinal Diseases through the Foundation’s Open Access Program
Research NewsThe benefits of genetic testing for IRD patients, how to participate in the Foundation’s Open Access program, and what to expect from the genetic testing process.
-
Unregulated Stem-Cell Therapy Causes Severe Vision Loss for Three Florida Women
Research News“…participation in a study for an emerging therapy that is not regulated by the FDA or another well-recognized regulatory agency like the European Medicines Agency in Europe, is fraught with dangers and can lead to unexpected serious consequences.”
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
